Apimeds extends maturity of three promissory notes to May 19, 2026

Apimeds Pharmaceuticals US, Inc.

Amended notes from Inscobee ($100k and $150k) and Apimeds Korea ($250k), total $500k principal.
Original maturity dates extended to May 19, 2026; interest remains 5% per annum.
May 2024 and August 2024 notes were due May 19, 2025; March 2025 note was due Dec 31, 2026 or upon NYSE listing.
Amendments executed on May 16, 2025, avoid imminent default on two notes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.